Dual Injection Approvals? A Comparison Of Indivior, Braeburn Buprenorphine Products
Executive Summary
US FDA might approve Indivior and Braeburn's injectable buprenorphine products simultaneously; here's a side-by-side look at the advantages and disadvantages of each.
You may also be interested in...
Keeping Track: Shutdown Edition
The latest drug development news and highlights from our US FDA Performance Tracker.
Braeburn's Buprenorphine Bid: Eight Dosing Options Part Of "All Hands On Deck" Approach
With an FDA decision on its buprenorphine injection expected by Jan. 19, Scrip spoke with Braeburn executives at J.P. Morgan about the company's justification for four once-weekly and four once-monthly doses, competition in the opioid use disorder (OUD) market and the need for more OUD therapies.
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
The latest drug development news and highlights from our US FDA Performance Tracker.